Business
Ginkgo Bioworks Reports First Quarter 2025 Financial Results
Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced its results for the first quarter ended March 31, 2025. The update, including a webcast slide presentation with additional details on the first quarter, as well as supplemental financial information will be available at investors.ginkgobioworks.com.
About this update from Ginkgo Bioworks Holdings, Inc.
[{"type":"text","content":"Ginkgo provides an update on its restructuring, including progress towards its expanded $250 million cost savings target","length":120,"tagName":"p","attribs":{}},{"type":"text","content":"Ginkgo and partners awarded $29 million contract by ARPA-H to develop distributed manufacturing of essential medicines using wheat germ cell-free expression systems","length":164,"tagName":"p","attribs":{}},{"type":"text","content":"BOSTON, May 6, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced its results for the first quarter ended March 31, 2025. The update, including a webcast slide presentation with additional details on the first quarter, as well as supplemental financial information will be available at investors.ginkgobioworks.com.","length":447,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Ginkgo Bioworks)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Ginkgo Bioworks)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":200,"url":"https://media.zenfs.com/en/prnewswire.com/fe3c2abd5acfb0739db965e53a5bec87"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/pD7D8Jpi1nYhM2EkNRaAzA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM1MztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/fe3c2abd5acfb0739db965e53a5bec87","width":400,"height":200}},"href":"https://mma.prnewswire.com/media/1583909/Ginkgo_Logo_Lockup.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"First Quarter 2025 Financial Results","length":36,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"First quarter 2025 Total revenue of $48 million, up from $38 million in the comparable prior year period, an increase of 27% primarily due to $7 million of non-cash revenue from the release of deferred revenue relating to the mutual termination of a customer agreement. Excluding this impact, Total revenue in the quarter was $41 million, an increase of 8% over the prior year period.","length":384,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Excluding the $7 million non-cash deferred revenue release, first quarter 2025 Cell Engineering revenue of $31 million, up from $28 million in the comparable prior year period, an increase of 10%, primarily dri...